Latest News

Media Release – Kiwis with MS ‘light years’ behind Aussie patients in treatment access and quality of life – study.

September 14, 2021 | Advocacy, Media, Study, Uncategorised

Media Release: 14 September 2021 (For Immediate Release) A new trans-Tasman study has highlighted alarming health inequities between New Zealand patients living with multiple sclerosis (MS) and their Australian counterparts — adding fuel to the ongoing fight for Pharmac to […]


Ethical use of Off-label disease-modifying therapies used in MS

August 3, 2021 | Education, Treatments, Uncategorised

The MS International Federation’s Atlas of MS showed that off-label disease-modifying therapies are used in at least 89 countries. This highlights the need for  transparent evidence-based guidelines to support clinical decision-making, pharmaceutical policies and reimbursement decisions.  Because there has been […]


Special Authority Criteria Amendment for DMTs

May 26, 2021 | Advocacy

Multiple Sclerosis NZ received several reports from concerned patients regarding the ambiguity of the Special Authority Criteria for DMTs. With the support of Dr John Mottershead, Pharmac were approached for clarification. Concern centred around whether bilateral aids qualify for use […]